



Corrigendum

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine. *Drug Des Devel Ther.* 2011;5:211–224.

The following sections are direct quotes from Cerny and Cerny (*Hum Vaccin.* 2009;5(4):200–205).

- The second, third, and fourth sentences of the abstract, as well as the last paragraph of the abstract, except for the second sentence (pp. 211)
- ‘Vaccines against nicotine’ (pp. 217)
- The first two paragraphs in ‘Vaccines against nicotine under evaluation in clinical trials’ (pp. 218) with the exception of the last sentence in the second paragraph
- ‘Cytos AG, Schlieren Switzerland’ (pp. 218)
- ‘Phase II study of vaccine NIB002’ (pp. 218)
- ‘Celtic pharma holdings LP’ (pp. 219) with the exception of the third-to-last and fourth-to-last sentences
- ‘Nabi Inc’ (pp. 220) with the exception of the last two sentences
- ‘Chilka Ltd and other competitors developing nicotine vaccines’ (pp. 220)
- ‘Further developments to expect’ (pp. 220)

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>